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1. Introduction   
Mammographic screening is the only important intervention for the early detection of breast 
cancer. The ability of mammography to detect incipient breast cancer depends on breast 
density. Hormonal treatments, affecting the breast radiological density, are an important 
risk factor interfering mammography. In the same time, mammographic density is currently 
being explored as a biomarker of response in primary and secondary prevention trials. 
Important considerations for chemoprevention studies include maximizing intrareader 
reliability and minimizing variance resulting from technical and physiologic factors (Fabian 
& Kimler, 2006). While technical factors for maximizing intrareader reliability and 
minimizing variance depend on classifications and technology, it is also important to 
evaluate the impact of physiologic and pharmacological factors  
2. Classifications of breast mammographic density   
Mammographic breast density reflects mammary gland development and structure. From 
the multiple methods that have been developed to assess mammographic density, Wolfe`s 
classification identified four categories: N1, P1, P2 and DY (Wolfe), with density increasing 
from N1 to DY, the greatest relative risk being associated with the DY pattern (Wolfe, 1976). 
The BIRADS system developed by the American College of Radiology classifies breasts as 1) 
almost entirely fatty, 2) scattered fibronodular tissue, 3) heterogeneously dense and 4) 
extremely dense (American College of Radiology [ACR], 1993). The proportion of women 
having BIRADS category 3 and 4 dramatically decreases with age. BIRADS semiquantitative 
classification has a suboptimal intrareader reliability (Fabian & Kimler, 2006). For greater 
intraobserver reliability, continuous, computer assisted measurements have a better 
performance, being more suitable for prevention studies (Fabian & Kimler, 2006). 
Byrne, using the mammograms from the Breast Cancer Detection Demonstration Project, 
developed a continuous density measurement system, in which the area of the breast 
occupied by increased density was measured relative to the total area of the breast (Byrne et 
al., 1995). Byrne`s classification has 5 categories of relative areas of increased 
mammographic density and give a better assessment of relative risk for breast cancer than 
the 4-category Wolfe classification. The authors observed that the area of increased density 
is a risk factor, while the total breast area is not. 
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Boyd et al divided breast density measurements into 6 categories similar to those of Byrne, 
using a similar computer-assisted system for detection of mammographic density (Boyd et 
al., 1995). 
Continuous density measurement system studies reported that the 10% of women who had 
>75% increased breast density had a 4 to 5-fold greater risk of breast cancer than women 
with no areas of increased breast density, after corrections for weight, reproductive and 
family history (Byrne et al.,1995; Boyd et al., 1995). Women with 50–75% area of density 
have a 2.5 to 3.0-fold increase in risk. Boyd et al. have suggested that the increase in relative 
risk estimates resulting from a breast density measurement lasts at least a decade (Fabian & 
Kimler, 2006; Boyd et al., 2002). 
This long-lasting influence of breast density further justifies the interest in evaluation of the 
impact of physiologic and pharmacological factors on mammografic breast density. 
 
Mammographic density category 
Wolfe  
 
Increased breast 
density 
N 1 P 1 P 2 DY 
Byrne 0 % 1-24 % 25-49 % 50-74 % ≥ 75 % 
Byrne 
(absolute 
density) 
0 cm2 1-13.9 
cm2 
14-22.9 
cm2 
23-33.9 cm2 34-52.9 cm2 > 53 cm2 
Boyd None < 10 % 10- <25 % 25- <50 % 50- <75 % ≥ 75 % 
 
Wolfe  
Percent of women 
exhibiting breast 
density patterns 
12 % 28 % 48 % 12 % 
Byrne 11 % 27 % 25 % 28 % 8 % 
Byrne 
(absolute 
density) 
Control group divided in six approximately equal groups 
Boyd 7 % 17 % 21 % 27 % 19 % 9 % 
 
Wolfe  
 
 
 
Adjusted odd ratio
1.0 1.68 2.83 2,73 
Byrne 
(adjusted for 
all 
confounding 
factors) 
 
1.0 
 
1.57 
 
2.47 
 
2.77 
 
4.35 
Byrne 
(absolute 
density) 
 
1.0 
 
1.48 
 
1.99 
 
2.08 
 
3.24 
 
3.35 
Boyd (all ages) 1.0 1.2 2.2 2.4 3.4 5.3 
Table 1. Risk of breast cancer development associated with mammographic density in 
Wolfe`s (Wolfe, 1976), Byrne`s (Byrne et al., 1995) and Boyd`s (Boyd et al., 1995) 
classifications (adapted from Fabian & Kimler, 2006). 
3. Endogenous influences on breast mammographic density   
Mammographic parenchymal patterns are a function of breast development. The 
development of breast is the sum of ducts and lobules genetic-induced development, under 
the control of endogenous factors, mainly endocrine. Estrogens are responsible for growth 
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and developments of the ducts, while the maturation of the breast acinus is progesteron-
dependent. Progesteron is responsible for water accumulation at the end of menstrual cycle, 
increasing the breast density and whiteness on mammography. Declining in levels of 
estrogens and progesteron in menopause is associated with a decrease in breast density, 
making it easier to be examined by mammography. 
4. Exogenous influences on breast mammographic density   
Exogenous hormonal influences on mammografic breast density are best reflected by 
positive associations of mammografic breast density with postmenopausal hormone 
replacement therapy (HRT) and inverse associations with tamoxifen (Ghosh & Vachon, 
2010).  
4.1 Hormone replacement therapy 
Hormone replacement therapy (HRT) increase the breast density (glandular tissue), which 
appears as white areas on a mammography, making microcalcifications and breast masses 
more difficult to detect, since breast abnormalities also appear as white areas on a 
mammography. 
HRT is used by perimenopausal and early postmenopausal women, in the age group in 
which the incidence of breast cancer is maximum. As HRT contains a wide range of 
therapeutic interventions, its effects on mammography will vary according to several 
variables: HRT users versus non-users, age and window of opportunity, duration and dose 
of therapy, estrogen versus estrogen+progestin therapy, continuos combined versus 
sequential HRT, type of progestin, transdermal versus oral HRT. 
The impact of HRT on mammographic screening is decreasing its sensibility, current use of 
HRT being associated with reduced sensitivity and specificity of mammographic breast 
cancer screening (Banks, 2001). Many studies suggest that current HRT users are more likely 
than non-users to have interval breast cancer (cancer occurring in the interval between 
screenings) (Banks, 2001; Cohen, 1997; Rosenberg et al., Litherland et al., 1999). Therefore, 
the benefit of mammographic screening may be reduced in HRT users, in terms of breast 
cancer mortality reduction, compared with non-users. Regarding the specificity of 
mammographic screening, many studies showed a lower specificity for current HRT users 
(Laya et al., 1996; Thurfjell et al., 1997), who may experience more false positive recall, 
compared with non-users (recalled for assessment after initial mammography, but found 
not to have breast cancer) (Clemons & Goss, 2001). Thurfjell et al (Thurfjell et al., 1997) 
divided current HRT users into three categories: less than 3 years of use, 3-6 years of use and 
more than 6 years of use. They reported specificities of 95%, 95%, and 92% respectively 
(p=0.046), revealing a trend for false positive recalls with increasing duration of use of HRT. 
These data are consistent with the study of Sala et al, who found that starting HRT pre- or 
perimenopausally and > 5 years of use will increase the probability of a high-risk 
mammographic density pattern, more difficult to evaluate (Sala et al., 2000). 
Current HRT users have an increased probability of having a high risk pattern of breast 
density (Sala et al., 2000; Persson et al., 1997; McTiernan et al., 2005; Greendale et al., 2003; 
Chlebowski et al., 2003; Boyd et al., 2006). Current estrogen + progestin therapy users and 
current estrogen-only therapy users had greater odds of having dense breasts (98% [1.87–
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2.09]) and 71%, respectively [1.56–1.87]), compared to never users (Aiello et al., 2006). Type 
of HRT regimen is an important factor, influencing breast mammographic density. 
Lundstrom E et al (Lundstrom E et al., 1999) found that increase in mammographic density 
was much more common among women receiving continuous estrogen + progestin HRT 
(52%) than among those receiving estrogen + progestin HRT (13%) and estrogen-only (18%) 
treatment. The increase in density was apparent already at first visit after the start of 
hormone replacement therapy. There was little change in mammographic status during 
long-term follow-up (Lundstrom E et al., 1999). 
Transdermal HRT use is associated with a significantly lower incidence of increased 
mammographic breast density and breast tenderness compared with oral HRT (Harvey et 
al., 2005). In Harvey`s study (2005), 202 postmenopausal women were randomized to 
transdermal (estradiol+norethindrone) or oral (estradion+norethistron acetate) HRT. 
Significantly fewer women using transdermal HRT had an increase in mammographic 
breast density or breast tenderness compared to oral HRT. Of the women using transdermal 
HRT, 39.1% had no change in breast density compared to 15.7% for women using oral HRT. 
Only 4% of women using transdermal HRT had a marked increase in density (>25%) 
compared to 15.7% of women using oral HRT. 
 
 
Fig. 1. Increase in mammographic breast density in a 53 years old patient on sequential 
combined hormonal therapy (1,5 mg estradiol transdermally+20 mg dydrogesterone orally). 
Left – mammography at baseline; right – mammography after 1 year of treatment. 
Procentual mammographic density raised from 23% to 55% (Russu et al., 2008). 
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The randomized, double-blinded PEPI trial (Greendale et al., 1999) compared the 
mammography before and after twelve months of treatment, for HRT patients versus 
placebo. Twenty percent of HRT patients had increased mammographic density, as 
compared to 0 % in placebo group. There was no difference in breast densities between 
continuous combined and sequential HRT groups. There was also no difference in breast 
densities with different progestins. Patients with estrogen-only therapy had a very small 
increase in breast density. 
The WHI Study (Chlebowski et al., 2003) found that, after one year of estrogen plus 
progestin therapy, the percent of abnormal mammography was higher in estrogen plus 
progestin therapy group, compared with placebo group (9,4% vs 5,4%; P<0.001), and the 
difference was maintained throughout the duration of the study. In each year thereafter, the 
percentage of women with abnormal mammograms was significantly higher in the estrogen 
plus progestin group vs the placebo group. For the whole study, 31.5% of women in the 
estrogen plus progestin group had at least 1 abnormal mammogram vs 21.2% of women in 
the placebo group (P<.001). Thus, even short-term estrogen plus progestin use resulted in a 
substantial increase in abnormal mammograms requiring medical evaluation. The risk for 
breast cancer parallels the percentage of abnormal mammography. The authors concluded 
that E+P therapy increased the number of breast cancer and the number of not necessary 
interventions for false positive mammography in this group. However, most of the studies 
found a lower mortality for HRT users compared with non-users. 
The Million Women Study showed that current users of HRT at recruitment were more 
likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-
1.75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Stopping HRT reduces breast 
cancer risk, as demonstrated in WHI study (Chlebowski et al., 2003), where the authors 
found that past users of HRT were not at an increased risk of incident or fatal disease (1.01 
[0.94-1.09] and 1.05 [0.82-1.34], respectively). 
Patients with estrogen-only therapy tend to have a small increase in breast density and 
lower risk for invasive breast cancer. In WHI study follow-up (La Croix et al., 2011), after 6 
years of equine estrogens use and a mean 10,7 years after baseline, estrogen-only therapy 
was associated with a lower risk for invasive breast cancer than the placebo group (hazard 
ratio, 0.77; 95% confidence interval, 0.62–0.95); moreover, among younger women, estrogen 
use was associated with lower risk for CHD (HR, 0.59; 95% CI, 0.38–0.90). However, this 
does not imply that estrogen-only therapy should be recommended at this time for breast 
cancer chemoprophylaxis (Beral et al., 2003; Kaunitz, 2011; Jungheim & Colditz, 2011). 
Progestin-releasing intrauterine devices are a type of hormone therapy addressed to women 
younger than 50 years of age, especially with associated uterine pathology (e.g., fibroids, 
menorrhagia).  
A retrospective, population-based, case-control study (Dinger et al., 2011), performed on 
25565 women (5113 breast cancer cases and 20452 controls) failed to observe any increase of 
breast cancer risk in levonorgestrel intrauterine device users.  
Combination of levonorgestrel intrauterine device and low-dose oral estradiol valerate 
was associated with a slight increase in mammographic breast density. Lundstrom et al 
(Lundstrom et al., 2006) assessed 20 healthy patients with levonorgestrel intrauterine 
device and 2 mg oral estradiol valerate and they found an apparent increase in breast 
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density in only 3 women (15%). However, there was no increase in proliferation, as 
expressed by the percentage of MIB-1-positive breast cells in fine-needle aspiration 
biopsies. Given the small number of cases, these results need to be confirmed by larger 
studies. 
Timing of HRT initiation influences the mammographic parenchymal patterns. Analizing a 
subgroup from EPIC-Norfolk cohort, Sala et al (Sala et al., 2000) found that women who are 
starting HRT, while still menstruating, were more likely to have a high-risk breast density 
pattern compared to women not exposed to HRT or to those who started HRT after 
menopause. A recent Million Women Study analysis update (Beral et al., 2011) focused on 
the influence of timing on breast cancer risk for the different treatment regimens. Relative 
risks were found to be higher if therapy was started before or soon after menopause than in 
the case of a longer interval between menopause and starting HRT (p < 0.001). Among 
current users of estrogen-only therapy, there was little or no increase in risk if use began 5 
years or more after menopause (RR 1.05, 95% CI 0.89–1.24), whereas risk was increased if 
use began before or within 5 years after menopause (RR 1.43, 95% CI 1.35–1.51). A similar 
pattern was seen for users of E+P (RR 1.53, 95% CI 1.38–1.70 vs. RR 2.04, 95% CI 1.95–2.14). 
The timing of initiation of HRT relative to that of menopause appears to be an important 
factor that modulates the risk of breast cancer. 
HRT effects on breast and mammography are reversible. After discontinuing hormone 
therapy, breast density decrease rapidly. Discontinuation of HRT a few weeks prior to 
mammography may improve mammographic performances. The rapid decrease in breast 
density after stopping HRT suggest that increased breast density in HRT users is different 
from increased breast density in non-users. Increased breast density in non-users reflects a 
genetic increased quantity of glandular and fibrous tissue, whereas increased breast density 
in HRT users may suggest a water retention at breast level, probably due to stromal 
changes, under hormonal influence (Alowami et al., 2003). In a retrospective study, Harvey 
at al analyzed breast density modifications after stopping HRT (Harvey et al., 1997). HRT-
induced mammographic changes disappeared two weeks after HRT discontinuation. 
However, twelve patients in their study did not experienced mammographic reversal after 
HRT discontinuation, and, on biopsy, one case of atypical hyperplasia and one case of 
ductal invasive carcinoma were found. More recent studies failed to observe an 
improvement in mammographic diagnostic accuracy, following HRT suspension. The 
Buist`s randomised trial revealed that HT suspension was associated with small changes in 
breast density and did not affect recall rates. There was no evidence to support short-term 
HT suspension before mammography (Buist et al., 2009). 
A few studies addressed the issue of reducing breast cancer risk in HRT population. Adding 
aromatase inhibitors to HRT may lower mammographic breast density in postmenopausal 
women. A small retrospective study (Mousa et al., 2008) demonstrated a statistically 
significant reduction in mammographic breast density occurred in the women who received 
hormone therapy plus an aromatase inhibitor letrozole, whereas no significant change was 
observed in the women receiving hormone therapy alone. Aromatase inhibitors could be 
good candidates for primary chemoprevention of breast cancer in postmenopausal women 
using hormone therapy (Mousa et al., 2008). 
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4.2 Oral contraceptive 
A special type of exogenous hormonal therapy is oral contraceptive (OC) use. Modern OC 
consist in a combination of ethinilestradiol (20µg or 30 µg) and different types of progestins. 
Oral contraceptive use is an issue of young women, mostly before age of 40, a time when 
mammographic screening begins. Therefore, studies evaluating the impact of COC on 
mammographic breast density are lacking.  
A Norwegian study (Gram et al., 2002) examined the relationship between oral 
contraceptive ever use and mammographic patterns among 3218 women, aged 40-56 years, 
who fulfilled a questionnaire about ever OC use, duration, and starting age of OC. Women 
ever having used OCs had an increased risk for high-risk mammographic patterns [OR 1.27; 
95% CI (1.0-1.6)], compared with those reporting never having used OCs. There was no 
relationship between different types of OC use (different doses) and high-risk patterns. 
Nulliparous women, who ever used OCs, were four times more likely [OR 4.65; 95% CI (2.1-
10.3)] to have high-risk patterns, compared with never users. 
Breast cancer lifetime-risk of oral contraceptive use was addressed in a large study (Hunter 
et al., 2010), performed on 116.608 female nurses, aged 25 to 42 years at enrollment in 1989, 
among which 1.344 cases of invasive breast cancer were diagnosed until 2001. There was no 
relationship between past use of any oral contraceptive and breast cancer risk [RR= 1.12; 
95% confidence interval (0.95-1.33)]. Current use of any oral contraceptive was only 
marginally related to a higher risk of breast cancer [RR=1.33; 95% confidence interval (1.03-
1.73)]. However, users of triphasic oral contraceptive, with levonorgestrel as the progestin, 
were exposed to an excess risk of breast cancer, as high as 3.05 [95% confidence interval 
(2.00-4.66); P < 0.0001]. The authors (Hunter et al., 2010) concluded that current use of oral 
contraceptives is associated with an excess risk of breast cancer, levonorgestrel-based 
triphasic contraceptives accounting for this risk elevation. 
4.3 Gonadotropin-releasing hormone agonists  
Gonadotropin-releasing hormone agonist (GnRHA) suppress ovarian function, decreasing 
circulating levels of estrogens, so it could be assumed that their administration would 
influence breast density. A special designed contraceptive study (Spicer et al., 1994) 
randomly assigned 21 patients, 27–40 years of age, with a 5-fold greater than normal risk of 
breast cancer, in a 2:1 ratio to special contraceptive group (14 women who received GnRHA 
(leucoprolide acetate) plus very low doses add-back conjugated estrogen and medroxy-
progesterone acetate) or to a control group (7 women). The authors found that women on 
the contraceptive regimen showed significant (P = 0.039) reduction in mammographic 
densities between the baseline and 1-year mammograms, compared with control group. In a 
follow-up of this study (Spicer et al., 1994), 12 months after completion of treatment, the 
mean percentage of mammographic density in the treated group was no different from that 
at baseline (P = 0.73). Reductions in mammographic density for this special contraceptive 
regimen (GnRHA plus low-dose add-back estrogen-progestin) persist only during treatment 
period. The densities return to baseline when the women resume normal menstrual cycles. 
A more recent study (Weitzel et al., 2007) performed on BRCA1 mutation high-risk patients, 
using GnRHA deslorelin, confirmed these data. Twelve months treatment with deslorelin, 
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plus low-dose add-back steroids, significantly decreased mammographic percent density in 
BRCA1 mutation carriers. This regimen may reduce breast cancer risk and improve the 
usefulness of mammographic surveillance by reducing density. 
4.4 Selective tissue estrogenic activity regulator   
Other forms of sistemic therapy for relief of climacteric symptoms and prevention of 
osteoporosis in postmenopausal women include selective tissue estrogenic activity regulator 
(STEAR), the most known being tibolone. Tibolone, a tissue-specific compound, constitutes 
an alternative for treatment in postmenopausal women (Moore, 1999).   
It appears that tibolone exerts minimal effects of the breast tissue and mammographic 
density. In a prospective, randomized, double-blind, placebo-controlled study (Lundström 
et al., 2002), breast density was increased in 46-50% of oral continuous combined HRT users, 
as opposed to only 2-6% in oral tibolone users and 0% in placebo group. The authors 
concluded that in contrast to estrogen/progestogen treatment, tibolone seems to exert little 
stimulation of breast tissue. 
According to Asia Pacific Tibolone Consensus Group, symptomatic HRT users with 
increased breast density that result in an unreadable mammogram could be switched on 
tibolone, in order to decrease mammographic density without losing the beneficial effects of 
HRT (Huang & Baber, 2010). 
However, the relationship between tibolone use and increased risk of breast cancer remains 
inconclusive (Opatrny et al., 2008). A population-based case-control study, GPRD database 
(Opatrny et al., 2008), found that tibolone do not increase the risk for breast cancer in 
postmenopausal women (RR 0.86; 95% CI 0.65-1.13). Even more, LIFT trial (Cummings et al., 
2008), which included 4538 osteoporotic postmenopausal women with no history of breast 
cancer, treated with tibolone, 1,25 mg/day, demonstrated a decreased risk of invasive breast 
cancer (RR = 0.32; 95% CI, 0.13 to 0.80; P=0.02).  
However, in women with a history of breast cancer, data from the LIBERATE (Kenemans et 
al., 2009) study show that tibolone (2,5 mg/day) does increase the risk of breast cancer 
recurrence. LIBERATE population of women is mostly using adjuvant systemic therapy, 
67% of women being on tamoxifen and 6.5% on aromatase inhibitors. Tibolone may interfere 
with the protective action of these agents, especially with the aromatase inhibitors, through 
an estrogen-agonistic action on dormant tumor cells. To date, tibolone should be 
contraindicated for women with a history of breast cancer. 
Although comparison is not possible between LIFT and LIBERATE study, dose seems to be 
an important issue with respect to breast cancer risk, when using tibolone for vasomotor 
symptoms relief and osteoporosis treatment. 
4.5 Selective estrogen-receptor modulators   
Selective estrogen-receptor modulators (SERMs), previously called antiestrogens, are drugs 
that competitively inhibit estrogen binding to estrogen receptors (ERs), and have mixed 
agonist and antagonist activity (depending on the target tissue). SERMs affect a variety of 
biologic processes regulated by activated estrogen receptor. Depending on the target tissue, 
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levels and types of ERs, and their structure, SERMs may exhibit either estrogen antagonist 
or estrogen agonist effects (Fabian & Kimler, 2005).  
Tamoxifen is a SERM with estrogen antagonist effects in the breast, weak estrogen agonist 
activity in the bone, cardiovascular system and CNS, and important estrogen agonist effects 
in the uterus, liver, and vagina.  
Most of the data regarding tamoxifen effects on mammographic breast density came from 
prevention studies, performed on populations at high-risk for breast cancer or with a history 
of breast cancer. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
randomized clinical trial of high-risk women, 5 years of tamoxifen therapy was shown to 
reduce invasive breast cancer risk by 49% and noninvasive breast cancer risk by 50% com-
pared with placebo (Fisher et al., 1998). 
Treatment with tamoxifen is associated with a reduction in breast density in both 
premenopausal and postmenopausal women (Ursin et al., 1996). However, the reduction in 
breast density in association with these factors has not yet been correlated with the 
reduction in the risk of breast cancer. 
Slanetz (Slanetz et al., 2004) described mammographic density decrease on tamoxifen and 
return to the baseline density following termination of the drug, so they postulated that 
decrease in breast density could reflect the sensitivity to tamoxifen and be a marker of 
therapeutic benefit associated with tamoxifen. The more radiolucent pattern by tamoxifen 
allow enhanced mammographic detection and may further add benefit for women. After 
discontinuation of tamoxifen, breast density is returning to its initial pattern. The clinical 
significance of resumption of a dense breast pattern following discontinuation of tamoxifen 
remains to be determined (Ursin et al., 1996). 
In high-risk populations (women with known breast cancer on adjuvant tamoxifen or 
women at high risk for breast cancer on tamoxifen for chemoprevention), tamoxifen 
produced a statistically significant reduction in mammmographic breast density and this 
reduction occurred more frequent in premenopausal than in postmenopausal women (54). 
In a study (Son & Oh, 1999), performed on breast cancer patients who have undergone 
surgery, 87% of premenopausal women with breast cancer had a decrease in parenchymal 
area with tamoxifen use, whereas only 29% of postmenopausal women experienced a 
decrease. 
A similar trend was observed in the Brisson`s study, performed on women with high-risk 
for breast cancer. Women younger than 50 experienced a decrease in parenchymal pattern 
classification in 67% of cases compared with 13% of postmenopausal women aged 50 or 
older (Brisson et al., 2000). 
The duration of tamoxifen treatment is important. In a nested case-control study performed 
for IBIS-1 participants, Cuzick et al. noticed that the reduction in dense area for women 
treated for 4,5 years with tamoxifen is double compared with women given placebo (Cuzick 
et al., 2004). The majority of breast density reduction occurred in the first 18 months of 
treatment. There was a significant interaction with age such that a minimal decrease in area 
of density was observed for women over 55 treated with tamoxifen, that is, 1% compared to 
13% for women younger than 45 (Cuzick et al., 2004). Importantly, reduction in breast 
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density predicted only one-third of the reduction in breast cancer incidence seen in 
prevention trials. 
While tamoxifen is mostly recommended by the oncologists, both for curative or preventive 
breast cancer treatment, other SERM`s, like raloxifen, are largely recommended by general 
practitioners for the treatment of postmenopausal osteoporosis. Raloxifene has higher 
affinity for estrogen receptor and more intense antagonistic effects (by blocking ER-
activating function domains, AF-1 and AF-2), than tamoxifen (which blocks only AF-2, but 
not AF-1) (Howell et al., 2001; Katzenellenbogen et al., 1996). 
In the STAR trial (Vogel et al., 2006), tamoxifen and raloxifene had equivalent effects in 
reducing risk of invasive breast cancer in all examined subgroups, including women with a 
history of atypical hyperplasia or LCIS, who had the highest annual rates of invasive breast 
cancer. Most of the STAR cases were diagnosed as a result of mammograms demonstrating 
increasing calcifications, in conditions of reducted breast density. Because the lesions were 
early detected and small, most were treated surgically with lumpectomy. 
In a retrospective analysis, performed on a subset of women enrolled in a multicenter, 
double-blind, randomized, placebo- and active-controlled phase 3 trial evaluating 
bazedoxifene for the treatment of postmenopausal osteoporosis, Harvey et al found that the 
changes in breast density with the newer SERM bazedoxifene 20 or 40 mg were similar to 
those with raloxifene 60 mg or placebo (Harvey et al., 2009). 
The analysis of extraskeletal outcomes (Gennari et al., 2009) of PEARL study indicated that 
lasofoxifene 0.25 mg and 0.5 mg reduces the risk of ER positive breast cancer (by 84% and 
67%, respectively). This effect was also evident for all breast cancers (a composite endpoint 
consisting of ER+, ER–, invasive, and ductal cancer in situ) with lasofoxifene 0.5 mg dose 
(65% and 79% risk reduction compared to placebo through 3 and 5 years, respectively) 
(Cummings et al., 2008). 
4.6 Aromatase inhibitors    
The aromatase inhibitors reduce breast and circulating estrogen levels in postmenopausal 
women. As a consequence, aromatase inhibitors may reduce mammographic breast density. 
Vachon et al randomized 106 postmenopausal women to either aromatase inhibitor letrozole 
or placebo after 5 years of tamoxifen (Vachon et al., 2007). After 9 to 15 months, no 
difference breast mammographic density was found between the 2 groups.  
MAP1 was a multicenter, randomized, double-blind, placebo-controlled, feasibility trial in 
which postmenopausal women with or without prior invasive breast cancer were 
randomized in a 2:1 ratio of letrozole (2.5 mg daily) or placebo for 12 months and followed 
for a total of 24 months. After one year treatment, letrozole does not appear to have a 
significant effect on mammographic percent breast density, compared with placebo (Cigler 
et al., 2010). Same author performed MAP 2 trial (Cigler et al., 2011) randomizing healthy 
postmenopausal women to exemestan (25 mg daily) or placebo for 12 months and followed 
them for a total of 24 months. The primary endpoint was change in percent breast density 
between the baseline and 12-month mammograms. For exemestan-treated patients, there 
was no significant difference in percent breast density from baseline to 6, 12, or 24 months; 
in the same time, there was no difference between exemestan and placebo group.  
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It was postulated that aromatase inhibitors could reduce mammographic breast density in 
women taking HRT. Two studies examined the influence of letrozole on MBD among 
postmenopausal women taking HRT: one found no change in percent MBD among 42 high-
risk women on either estrogen alone or combination HRT (estrogen and progestins) after 
taking 2.5 mg letrozole per day for 6 months (64), whereas the other study found a reduction 
among women on low-dose combination therapy who were taking letrozole (2.5 mg) 3 times 
weekly for a median of 24 (range, 2-63) months (6.8% vs 1.4% reduction) (Mousa et al., 2008). 
The effects of aromatase inhibitors on breast density, as well as on breast cancer risk, still 
require further investigation (Becker & Kaas, 2009). 
4.7 Phytoestrogens    
Phytoestrogens are plant derived substances that are structurally and functionally similar to 
estrogens and are found in many foods. They exhibit both weak estrogen and anti-
estrogenic activity; therefore, they act as natural SERMs. There are 3 classes of 
phytoestrogens: isoflavonoids, coumestans and ligans (Malik & Prakash, 2004).  
Maskarinec et al randomly assigned 220 premenopausal women, aged 39 – 46 years old, to 
soy intake intervention group or control group (Maskarinec et al., 2004). After 2 years of 
intervention, the authors observed no significant differences in mammographic densities by 
intervention status. 
Association between regular green tea intake and high soy intake may have beneficial 
effects on the breast density. Wu, Ursin et al assessed the effects of the effects of regular 
green tea and soy intake on mammographic density, in a cross-sectional study performed on 
3315 Chinese women in Singapore (Wu et al., 2008). For daily green tea drinkers, percent 
mammographic density was statistically significantly lower than for non-tea drinkers (19.5 
% versus 21.7%; P = 0.002), even after adjustment for soy (P = 0.002). There was no 
association between black tea intake and percent mammographic density. Very high soy 
intake was associated with lower percent density only among postmenopausal women 
(compared normal or low soy intake; 18.9% versus 20.5%, P = 0.035); however, after 
adjustment for green tea intake, this association was no longer statistically significant (P = 
0.52). 
5. Conclusion  
Mammographic density is a well-known risk factor for breast cancer, although the 
biologic basis of the relationship between breast cancer risk and increased mammographic 
density is not yet completely understood. Nor is the mechanism by which hormonal 
therapy influences mammographic breast density. Despite the beneficial effects on 
menopausal symptoms and osteoporosis, it is the fear of breast cancer that make 
menopausal women reluctant to take hormone therapy. Characterizing the association 
between breast density and hormonal influences may enhance the understanding of how 
mammographic density influences breast cancer risk for both pre- and postmenopausal 
women. Mammographic density reflecting directly the changes at the breast level, the 
influences generated by the associated therapies should be taken into account in screening 
and diagnostic programs.  
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